| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
CDK9/cyclinT1 6 nM (IC50)
|
|---|---|
| ln Vitro |
RNA Pol II's downstream phosphorylation at Ser2 and Ser7 was significantly reduced, while phosphorylation at Ser5 was lowered, after 6 hours of treatment with KB-0742 (0.1–10 μM; 22Rv1 cells). Beginning around the 6-hour mark of treatment, there is a considerable reduction in the levels of the androgen receptor (AR)-FL and AR-V proteins worldwide, along with a decrease in phospho-AR (Ser81) levels[1]. Treatment with KB-0742 (48–72 hours) has cytostatic effects on leukemia and prostate cancer cell lines. With GR50s of 0.183 μM and 0.288 μM for 22Rv1 cells and MV-4-11 AML cells, respectively, KB -0742 exhibits antiproliferative activity[1]. KB-0742 quickly suppresses emerging transcription in 22Rv1 cells, specifically reducing short half-live transcripts and AR-driven cancerous programs[1].
|
| ln Vivo |
In 22Rv1 human prostate cancer cell line-derived xenograft (CDX) models, KB-0742 (3-30 mg/kg; po; daily; over 21 days) dramatically reduces tumor burden while being well tolerated even at high doses[1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: 22Rv1 cells Tested Concentrations: 0.1 μM, 0.5 μM, 1 μM, 10 μM Incubation Duration: 6 hrs (hours) Experimental Results: Significant reduction of downstream phosphorylation of RNA Pol II at Ser2 and Ser7, and diminished phosphorylation at Ser5. |
| Animal Protocol |
Animal/Disease Models: Male CB17-SCID (severe combined immunodeficient) mouse injected with 22Rv1 human prostate cancer cells[1]
Doses: 3 mg/kg, 10 mg/kg, and 30 mg /kg Route of Administration: po; daily; over 21 days Experimental Results: Dramatically diminished tumor growth in castration-resistant prostate cancer (CRPC). |
| References |
[1]. André Richters, et al. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2020 Oct 20;S2451-9456(20)30380-9.
|
| Molecular Formula |
C16H27CL2N5
|
|---|---|
| Molecular Weight |
360.33
|
| Elemental Analysis |
C, 53.33; H, 7.55; Cl, 19.68; N, 19.44
|
| CAS # |
2416874-75-2
|
| Related CAS # |
2416874-75-2 (HCl);2416873-83-9;
|
| Appearance |
Solid powder
|
| SMILES |
CCC(CC)C1=NC2=CC=NN2C(N[C@@H]3C[C@@H](N)CC3)=C1.Cl.Cl
|
| InChi Key |
OTUPXOLLHVLWQF-NJHZPMQHSA-N
|
| InChi Code |
InChI=1S/C16H25N5.2ClH/c1-3-11(4-2)14-10-16(19-13-6-5-12(17)9-13)21-15(20-14)7-8-18-21;;/h7-8,10-13,19H,3-6,9,17H2,1-2H3;2*1H/t12-,13-;;/m0../s1
|
| Chemical Name |
(1S,3S)-N1-(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine dihydrochloride
|
| Synonyms |
KB-0742; KB0742; KB 0742 2HCl; KB 0742 dihydrochloride; KB 0742 hydrochloride;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 100 mg/mL (277.52 mM)
DMSO : 62.5 mg/mL (173.45 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (277.52 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7752 mL | 13.8762 mL | 27.7523 mL | |
| 5 mM | 0.5550 mL | 2.7752 mL | 5.5505 mL | |
| 10 mM | 0.2775 mL | 1.3876 mL | 2.7752 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
